Medicine
Cosentyx 125 mg/5 mL injection
Cosentyx 125 mg/5 mL injection is a prescription medicine containing Secukinumab for intravenous use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Refrigerate COSENTYX at 2ºC to 8ºC (36ºF to 46ºF). Do not freeze. If removed…
Key facts
- Active ingredient (INN)
- Secukinumab
- Brand
- Cosentyx
- Strength
- 125 mg/5 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 5 mL
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Refrigerate COSENTYX at 2ºC to 8ºC (36ºF to 46ºF). Do not freeze. If removed from refrigeration, COSENTYX Sensoready pen and prefilled syringes (150 mg/mL, 75 mg/0.5 mL): May be stored for up to 4 days at room temperature not to exceed 30°C (86°F). Write the date COSENTYX is removed from and returned to the refrigerator in the space provided on the carton.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AC10 Secukinumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 October 2023
- Identifiers
- RxCUI 1599792, 1599797, 1653241 +7DailyMed set ID 77c4b13e-7df3-42d4-81db-3d0cddb7f67aNDC 0078-1168Application BLA761349
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 mL in 1 vial, glass | 0078-1168-61 | Novartis Pharmaceuticals | 6 October 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Secukinumab
Clinical summary
Secukinumab is an interleukin-17A antagonist indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy, among other approved uses. MedsAcross supplies Secukinumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SecukinumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- COSENTYX prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Cosentyx: European public assessment report (EPAR) · European Medicines Agency
Need Cosentyx 125 mg/5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.